Table 4.
Placebo (N = 8) | Luseogliflozin | ||||
---|---|---|---|---|---|
0.5 mg (N = 8) | 1 mg (N = 8) | 2.5 mg (N = 8) | 5 mg (N = 8) | ||
Any adverse event, n | 0 | 3 | 1 | 1 | 2 |
Any related event, n | 0 | 1 | 0 | 0 | 0 |
Constipation | 0 | 1 | 0 | 0 | 0 |
Diarrhea | 0 | 1 | 0 | 0 | 0 |
Dermatitis contact | 0 | 0 | 1 | 0 | 0 |
Pruritus | 0 | 1 | 0 | 0 | 0 |
Headache | 0 | 1 | 0 | 0 | 1 |
Blood urine present | 0 | 0 | 0 | 0 | 1 |
ALT increased | 0 | 0 | 0 | 1 | 0 |
γ-GTP increased | 0 | 0 | 0 | 1 | 0 |
Values are presented as the number of subjects
ALT alanine aminotransferase, γ-GTP gamma-glutamyltransferase